Capital Group Investment Management’s Ascendis Pharma A/S ASND Stock Holding History

Capital Group Investment Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$775K	Hold	2,906	–	–	0.12%	121
2026 Q1	$665K	Hold	2,906	–	–	0.11%	123
2025 Q4	$620K	Sell	2,906 -976	-25%	-$202K	0.1%	128
2025 Q3	$772K	Hold	3,882	–	–	0.13%	126
2025 Q2	$670K	Hold	3,882	–	–	0.12%	125
2025 Q1	$605K	Buy	3,882 +273	+8%	+$39K	0.12%	122
2024 Q4	$497K	Buy	+3,609	New	+$475K	0.09%	128

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Capital Group Investment Management's ASND Position: Q2 2026 in Review

Capital Group Investment Management held its Ascendis Pharma A/S (ASND) position steady in Q2 2026 at 2,906 shares worth $775K. The position accounts for 0.12% of the portfolio, ranked #121.

Capital Group Investment Management first reported a position in ASND in Q4 2024 and has held it in 7 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Capital Group Investment Management held 2,906 shares of Ascendis Pharma A/S worth $775K as of Q2 2026.
Capital Group Investment Management left its Ascendis Pharma A/S share count unchanged in Q2 2026.
Ascendis Pharma A/S made up 0.12% of Capital Group Investment Management's portfolio in Q2 2026, its #121 holding.
Capital Group Investment Management first reported a position in Ascendis Pharma A/S in Q4 2024 and has held it in 7 quarters since.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Capital Group Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.